NTLA

Intellia Therapeutics, Inc. (NTLA) | Rumor.io

Intellia Therapeutics

NTLA

Attention (50-day avg)0.01%

Attention rank (50-day avg)#500

Bullish sentiment (50-day avg)79%

Price to earnings ratio-3

Market capitalization1.6B

Earnings per share-3.34

Dividend yield (TTM)—

Revenue (annual)67.7M

Net income (annual)-412.7M

Social

What share of all stock conversation is about NTLA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% -0.01	0.01% +0	0.01% -0.01

Sep 24

Intellia Therapeutics, Inc. (NTLA) was relatively strong at -2% yesterday despite the biotech market's decline.
The company's potential for growth is improved by the discovery of a new gene editing technology, ART, which may disrupt the market and increase NTLA's value.
Intellia is expected to profit from the discovery of ART, which is still in the preliminary stages, and may take around 7-12 years to become a viable treatment option.

Generated by AI

Sentiment

Of the messages about NTLA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	71.07% -24.32	77.39% +3.98	62.8% -7.83
Bearish	0%	28.93% +24.32	22.61% -3.98	37.2% +7.83

Bullish· Sep 8

The FDA has accepted Intellia's BLA for Lonvo-Z with Priority Review, with a PDUFA date of March 10, 2027, and the company has secured enough cash runway to commercialization.
The successful approval of Lonvo-Z would validate Intellia's CRISPR platform, potentially creating substantial value across its broader pipeline and beyond a single product.
The stock is expected to experience a significant run-up in the coming months, with one analyst expecting it to climb 5% a month before March, and another predicting a 20% day on no news.

Bearish· Jul 20

$NTLA is retesting the November lows at $7.95, and may find support at $0, making it an easy short trade with the stock likely to go lower over the long run.
Wolfe Research has downgraded $NTLA from Outperform to Peer Perform, and then to Underperform, citing big moves up to $17/$18 that have not been sustained, and indicating a bearish trend.
The 14-day stochastic reading for $NTLA is 1X3, a rare and ominous reading that suggests a "collective action" to take the stock lower and force out leveraged longs, such as a hedged fund or two, and may be a "run on the bank" that could lead to a significant price drop.

Generated by AI

Topics

Of the messages about NTLA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	50%	98.12%	17.59%
Technical Analysis	—	44.44%	1.3%	3.85%
Analysts	—	0%	0.43%	36.15%
Earnings	—	0%	0%	0.56%
Controversies	—	5.56%	0.14%	6.3%
Macro	—	0%	0%	35.55%

Earnings· Aug 1

Intellia Therapeutics reported a loss of $0.52 per share, beating estimates of a $0.57 loss.
The company's revenue was $7.68 million, beating expectations.
Intellia Therapeutics beat earnings per share loss estimates by $0.03 and revenue estimates.

Analysts· Feb 28

JPMorgan downgraded Intellia Therapeutics (NTLA) to Neutral from Overweight with a price target of $13, down from $45.
Several analysts, including Barclays, Wells Fargo, and Citigroup, have updated their ratings for Intellia Therapeutics (NTLA) to Overweight or Neutral with price targets ranging from $13 to $60.
Goldman Sachs downgraded Intellia Therapeutics to Sell from Neutral with a price target of $9, citing a "challenging" commercial outlook and awaiting Phase 3 data from the company's programs.

Announcements· Apr 27

Intellia Therapeutics ($NTLA) announced positive results from its global Phase 3 HAELO clinical trial of lonvo-z (formerly known as $NTLA-2002) in hereditary angioedema (HAE), meeting its primary endpoint with an 87% reduction in attacks.
The company initiated a rolling BLA submission to the FDA for lonvo-z, a one-time treatment for HAE, with a potential launch in H1 2027.
Intellia's Phase 3 HAELO trial marked a global first for an in vivo CRISPR therapy, with lonvo-z demonstrating a 62% of patients attack-free and treatment-free at 6 months.

Controversies· Mar 2

Intellia Therapeutics' (NTLA) FDA lift of clinical hold on MAGNITUDE Phase 3 trial in ATTR-CM allows enrollment to resume under tighter liver-safety monitoring.
The trial's protocol was adjusted to include enhanced monitoring of liver laboratory tests and guidance for short-term steroid treatment if elevated liver transaminases are observed.
The FDA's decision was based on Intellia's alignment with the agency on mitigation measures, which also includes monitoring for recent cardiovascular instability and exclusions for patients with end-stage heart failure and hemodynamically fragile conditions.

Technical Analysis· Jul 1

A head and shoulders pattern may be forming, with a possible price drop to $110-$120.
If the price dips below yesterday's open of $155, there may be no meaningful resistance until $130.
The area between the 50-day EMA and the 200-day EMA is a key support level, with price previously bouncing off this area during a correction.

Generated by AI

Community

Of the messages about NTLA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	48.85%	67.4%	68.16%
Newcomers	0%	51.15%	32.6%	31.84%

Regulars· Sep 9

The FDA has accepted Intellia Therapeutics' BLA for lonvo-z with priority review, and the PDUFA target action date is set for March 10, 2027.
The company's cash runway is now secure, and the best-case scenario for ATTR safety finding has been met, which could lead to a stock price of $38 by year-end 2027.
The OrbiMed agreement provides significant milestones for Intellia Therapeutics, including $75M upon approval, $120M on commercialization and revenue milestones, and $225M tied to milestones on the new drug, which could impact the stock price.

Newcomers· Aug 26

Many newcomers are excited about Intellia Therapeutics' potential for a short squeeze, with some expecting a rise to $14 per share.
Newcomers are anticipating a BLA (Biologics License Application) from the FDA, with some estimating acceptance in early November.
The asset is experiencing a bullish trend, with a golden cross forming and rising RSI and MACD indicators, suggesting potential further upside.

Generated by AI

News

Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity

22h agoBarchart.com

Could This Cathie Wood Stock Soar in 2027? | The Motley Fool

This biotech has grabbed plenty of headlines recently.

2d agoThe Motley Fool

Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA)

Intellia update: Claude AI flags a gene-editing setup but can’t replicate it. Lonvo-z targets a 2027 launch; Nex-z enrollment rebounds. Click for more on NTLA stock.

3d agoSeeking Alpha

Gene editing stocks fall on Anthropic’s CRISPR-like discovery

Gene editing stocks fall as Anthropic’s (ANTHRO) AI model Claude discovers a new enzyme system similar to the gene-editing tool CRISPR. Read more here.

6d agoSeeking Alpha

Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy

Intellia Therapeutics (NasdaqGM:NTLA) said the FDA accepted its Biologics License Application for lonvo-z for hereditary angioedema. The agency granted Priority Review status, positioning lonvo-z as a potential first in vivo CRISPR-based therapy in the U.S. The FDA does not plan to convene an advisory committee, with review supported by positive Phase 3 data and multiple global designations. The FDA's Priority Review of lonvo-z for hereditary angioedema is a key regulatory event to weigh...

7d agoYahoo Finance

Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances

11d agoYahoo Finance

Also Discussed

Investors talking about NTLA also mention

#	Name	Attention
1	Editas Medicine, Inc.EDIT	0%+0
2	CRISPR Therapeutics AGCRSP	0%-0.01
3	Beam Therapeutics IncBEAM	0.02%+0.02
4	Caribou Biosciences, Inc.CRBU	0%new
5	Prime Medicine, Inc.PRME	0%-0.01
6	VERV - Verve Therapeutics, Inc.	——
7	SGMO - Sangamo Therapeutics, Inc.	——
8	Precision BioSciences, Inc.DTIL	0%new
9	Twist Bioscience CorporationTWST	0%-0.02
10	Cellectis S.A. ADRCLLS	0%new

Intellia Therapeutics, Inc.

Healthcare
Biotechnology

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing medicines built on CRISPR/Cas9 technology. Intellia Therapeutics develops both in vivo therapies, which edit genes inside the body, and ex vivo cell therapies, where cells are edited outside the body before being returned to the patient. Its current programs are centered on severe genetic and immune-related diseases, including rare disorders such as transthyretin amyloidosis and hereditary angioedema, as well as selected oncology and autoimmune applications. The company’s broader role in the market is to advance potentially curative treatment approaches that address the root cause of disease rather than symptoms. Intellia Therapeutics operates as a research-driven biopharmaceutical company, with a business model centered on clinical development, collaboration, and platform-based innovation in genetic medicine.

Website

Location

40 Erie Street

Cambridge, MA, 02139

United States

Social

What share of all stock conversation is about NTLA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% -0.01	0.01% +0	0.01% -0.01

Sep 24

Intellia Therapeutics, Inc. (NTLA) was relatively strong at -2% yesterday despite the biotech market's decline.
The company's potential for growth is improved by the discovery of a new gene editing technology, ART, which may disrupt the market and increase NTLA's value.
Intellia is expected to profit from the discovery of ART, which is still in the preliminary stages, and may take around 7-12 years to become a viable treatment option.

Generated by AI

Sentiment

Of the messages about NTLA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	71.07% -24.32	77.39% +3.98	62.8% -7.83
Bearish	0%	28.93% +24.32	22.61% -3.98	37.2% +7.83

Bullish· Sep 8

The FDA has accepted Intellia's BLA for Lonvo-Z with Priority Review, with a PDUFA date of March 10, 2027, and the company has secured enough cash runway to commercialization.
The successful approval of Lonvo-Z would validate Intellia's CRISPR platform, potentially creating substantial value across its broader pipeline and beyond a single product.
The stock is expected to experience a significant run-up in the coming months, with one analyst expecting it to climb 5% a month before March, and another predicting a 20% day on no news.

Bearish· Jul 20

$NTLA is retesting the November lows at $7.95, and may find support at $0, making it an easy short trade with the stock likely to go lower over the long run.
Wolfe Research has downgraded $NTLA from Outperform to Peer Perform, and then to Underperform, citing big moves up to $17/$18 that have not been sustained, and indicating a bearish trend.
The 14-day stochastic reading for $NTLA is 1X3, a rare and ominous reading that suggests a "collective action" to take the stock lower and force out leveraged longs, such as a hedged fund or two, and may be a "run on the bank" that could lead to a significant price drop.

Generated by AI

Topics

Of the messages about NTLA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	50%	98.12%	17.59%
Technical Analysis	—	44.44%	1.3%	3.85%
Analysts	—	0%	0.43%	36.15%
Earnings	—	0%	0%	0.56%
Controversies	—	5.56%	0.14%	6.3%
Macro	—	0%	0%	35.55%

Earnings· Aug 1

Intellia Therapeutics reported a loss of $0.52 per share, beating estimates of a $0.57 loss.
The company's revenue was $7.68 million, beating expectations.
Intellia Therapeutics beat earnings per share loss estimates by $0.03 and revenue estimates.

Analysts· Feb 28

JPMorgan downgraded Intellia Therapeutics (NTLA) to Neutral from Overweight with a price target of $13, down from $45.
Several analysts, including Barclays, Wells Fargo, and Citigroup, have updated their ratings for Intellia Therapeutics (NTLA) to Overweight or Neutral with price targets ranging from $13 to $60.
Goldman Sachs downgraded Intellia Therapeutics to Sell from Neutral with a price target of $9, citing a "challenging" commercial outlook and awaiting Phase 3 data from the company's programs.

Announcements· Apr 27

Intellia Therapeutics ($NTLA) announced positive results from its global Phase 3 HAELO clinical trial of lonvo-z (formerly known as $NTLA-2002) in hereditary angioedema (HAE), meeting its primary endpoint with an 87% reduction in attacks.
The company initiated a rolling BLA submission to the FDA for lonvo-z, a one-time treatment for HAE, with a potential launch in H1 2027.
Intellia's Phase 3 HAELO trial marked a global first for an in vivo CRISPR therapy, with lonvo-z demonstrating a 62% of patients attack-free and treatment-free at 6 months.

Controversies· Mar 2

Intellia Therapeutics' (NTLA) FDA lift of clinical hold on MAGNITUDE Phase 3 trial in ATTR-CM allows enrollment to resume under tighter liver-safety monitoring.
The trial's protocol was adjusted to include enhanced monitoring of liver laboratory tests and guidance for short-term steroid treatment if elevated liver transaminases are observed.
The FDA's decision was based on Intellia's alignment with the agency on mitigation measures, which also includes monitoring for recent cardiovascular instability and exclusions for patients with end-stage heart failure and hemodynamically fragile conditions.

Technical Analysis· Jul 1

A head and shoulders pattern may be forming, with a possible price drop to $110-$120.
If the price dips below yesterday's open of $155, there may be no meaningful resistance until $130.
The area between the 50-day EMA and the 200-day EMA is a key support level, with price previously bouncing off this area during a correction.

Generated by AI

Community

Of the messages about NTLA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	48.85%	67.4%	68.16%
Newcomers	0%	51.15%	32.6%	31.84%

Regulars· Sep 9

The FDA has accepted Intellia Therapeutics' BLA for lonvo-z with priority review, and the PDUFA target action date is set for March 10, 2027.
The company's cash runway is now secure, and the best-case scenario for ATTR safety finding has been met, which could lead to a stock price of $38 by year-end 2027.
The OrbiMed agreement provides significant milestones for Intellia Therapeutics, including $75M upon approval, $120M on commercialization and revenue milestones, and $225M tied to milestones on the new drug, which could impact the stock price.

Newcomers· Aug 26

Many newcomers are excited about Intellia Therapeutics' potential for a short squeeze, with some expecting a rise to $14 per share.
Newcomers are anticipating a BLA (Biologics License Application) from the FDA, with some estimating acceptance in early November.
The asset is experiencing a bullish trend, with a golden cross forming and rising RSI and MACD indicators, suggesting potential further upside.

Generated by AI

Intellia Therapeutics

Social

Sep 24

Bullish· Sep 8

Bearish· Jul 20

Earnings· Aug 1

Analysts· Feb 28

Announcements· Apr 27

Controversies· Mar 2

Technical Analysis· Jul 1

Regulars· Sep 9

Newcomers· Aug 26

Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity

Could This Cathie Wood Stock Soar in 2027? | The Motley Fool

Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA)

Gene editing stocks fall on Anthropic’s CRISPR-like discovery

Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy

Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances

Also Discussed

Intellia Therapeutics, Inc.

Company Information

Location

Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity

Could This Cathie Wood Stock Soar in 2027? | The Motley Fool

Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA)

Gene editing stocks fall on Anthropic’s CRISPR-like discovery

Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy

Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances

Also Discussed

Social

Sep 24

Bullish· Sep 8

Bearish· Jul 20

Earnings· Aug 1

Analysts· Feb 28

Announcements· Apr 27

Controversies· Mar 2

Technical Analysis· Jul 1

Regulars· Sep 9

Newcomers· Aug 26